文章：

PARP抑制剂在胃癌治疗中的进展与挑战

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

原文发布日期：24 October 2023

DOI: 10.3390/cancers15215114

类型: Article

开放获取: 是

英文摘要：

Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome prognosis and notable mortality. As a result, there is an urgent need for novel therapeutic approaches to address GC. Recent targeted sequencing studies have revealed frequent mutations in DNA damage repair (DDR) pathway genes in many GC patients. These mutations lead to an increased reliance on poly (adenosine diphosphate-ribose) polymerase (PARP) for DNA repair, making PARP inhibitors (PARPi) a promising treatment option for GC. This article presents a comprehensive overview of the rationale and development of PARPi, highlighting its progress and challenges in both preclinical and clinical research for treating GC.

摘要翻译： 

胃癌是一种常见且具有侵袭性的消化系统恶性肿瘤，其恶性程度高且异质性显著。尽管过去几十年在提高生存率方面取得进展，胃癌的预后仍不容乐观，死亡率居高不下。因此，亟需开发新型治疗策略以应对胃癌。近期靶向测序研究表明，许多胃癌患者的DNA损伤修复通路基因存在高频突变。这些突变导致肿瘤细胞对聚腺苷二磷酸核糖聚合酶的修复依赖性增强，使得PARP抑制剂成为胃癌治疗的潜在选择。本文系统综述了PARP抑制剂的作用机制与发展历程，重点阐述其在胃癌临床前及临床研究中的进展与挑战。

原文链接：

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer